Share on StockTwits

Oncomed Pharmaceuticals (NASDAQ:OMED) Director Denise Pollard-Knight sold 3,252 shares of the company’s stock on the open market in a transaction dated Wednesday, June 25th. The shares were sold at an average price of $23.56, for a total transaction of $76,617.12. The sale was disclosed in a legal filing with the SEC, which is available at this link.

A number of research firms have recently commented on OMED. Analysts at Mizuho reiterated a “buy” rating on shares of Oncomed Pharmaceuticals in a research note on Friday, June 13th. Separately, analysts at Zacks upgraded shares of Oncomed Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Tuesday, May 13th. They now have a $23.10 price target on the stock. Finally, analysts at Jefferies Group cut their price target on shares of Oncomed Pharmaceuticals from $50.00 to $48.00 in a research note on Friday, May 9th. One research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Oncomed Pharmaceuticals currently has an average rating of “Buy” and an average target price of $37.78.

Shares of Oncomed Pharmaceuticals (NASDAQ:OMED) traded down 2.62% on Friday, hitting $22.69. 129,412 shares of the company’s stock traded hands. Oncomed Pharmaceuticals has a 1-year low of $12.07 and a 1-year high of $42.34. The stock’s 50-day moving average is $23.26 and its 200-day moving average is $29.03. The company’s market cap is $670.6 million.

Oncomed Pharmaceuticals (NASDAQ:OMED) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.34. Analysts expect that Oncomed Pharmaceuticals will post $-0.76 EPS for the current fiscal year.

OncoMed Pharmaceuticals, Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.